WHO ICTRP trial
A study about the effects of the drug Vorinostat (Zolinza) in patients with a…
EUCTR2016-000782-22-AT · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2016-000782-22-AT |
|---|---|
| Public title | A study about the effects of the drug Vorinostat (Zolinza) in patients with a previously treated, recurring special form of uterine cancer (sarcoma). |
| Scientific title | A pilot study of peroral Vorinostat (Zolinza) in patients with refractory histone deacetylase-positive uterine sarcoma. - SAHA-Pilot-2016 |
| Primary sponsor | Medical University of Graz |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Austria |
| Conditions | Uterine sarcoma;Therapeutic area: Diseases [C] - Cancer [C04] |
| Interventions | Trade Name: Zolinza Product Name: Zolinza Pharmaceutical Form: Capsule, hard INN or Proposed INN: Vorinostat CAS Number: 149647-78-9 Other descriptive name: VORINOSTAT, SAHA Concentration unit: mg milligram(s) Concentration type: equal… |
| Registration date | Jul 12, 2016 |
| Target size | 8 |
| Secondary IDs | SAHA-Pilot-2016 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: